{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T16:03:11Z","timestamp":1771516991001,"version":"3.50.1"},"reference-count":33,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose:<\/jats:title>\n                    <jats:p>In this study, we examined the effectiveness of methylphenidate on emotion dysregulation among children with attention-deficit\/hyperactivity disorder (ADHD), and the strategy of switching to or adding aripiprazole for nonresponders.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We conducted a 3-step, 10-week, open-label trial including children (6\u201318\u2009years old) with ADHD and emotion dysregulation, defined according to the Child Behavior Checklist-Dysregulation Profile. In step 1, patients received methylphenidate treatment for 4\u2009weeks. In step 2, nonresponders were started on aripiprazole treatment for 4\u2009weeks. Nonresponders in step 2 entered step 3, receiving a combination of methylphenidate and aripiprazole for 2\u2009weeks. The primary outcome was the change from baseline in emotion dysregulation, assessed using the irritability subscale of the Aberrant Behavior Checklist. Secondary outcomes included the change from baseline in ADHD symptoms, cross-domain-associated symptoms, adaptive functioning, and neurocognitive profiles.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Among the 30 enrolled patients, 22 (73.3%) responded to methylphenidate (group MR), while 8 entered step 2 (aripiprazole treatment for methylphenidate nonresponders; group MN). In step 2, 5 patients responded to aripiprazole, while 2 patients entered step 3 and received methylphenidate plus aripiprazole. Patients who responded to methylphenidate or aripiprazole exhibited significant improvements in emotion dysregulation (Hedges' g: 2.62 and 1.30, respectively) and school adaptation. Emotion dysregulation severity was correlated with oppositional defiant disorder symptoms, but not with core symptoms of ADHD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>The nature of emotion dysregulation in ADHD is heterogeneous regarding the response to methylphenidate. For most patients, methylphenidate significantly improved emotion dysregulation. Aripiprazole could be effective and safe for methylphenidate nonresponders.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/jcp.0000000000002002","type":"journal-article","created":{"date-parts":[[2025,4,16]],"date-time":"2025-04-16T15:00:07Z","timestamp":1744815607000},"page":"356-363","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["The Role of Methylphenidate and Aripiprazole in the Treatment of Emotion Dysregulation in Children With ADHD"],"prefix":"10.1097","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0826-4847","authenticated-orcid":false,"given":"Pei-Yin","family":"Pan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8501-3833","authenticated-orcid":false,"given":"Chin-Bin","family":"Yeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2025,4,16]]},"reference":[{"key":"bib1-20260219","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/jcpp.12899","article-title":"Practitioner review: emotional dysregulation in attention-deficit\/hyperactivity disorder - implications for clinical recognition and intervention","volume":"60","author":"Faraone","year":"2019","journal-title":"J Child Psychol Psychiatry"},{"key":"bib2-20260219","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1176\/appi.ajp.2013.13070966","article-title":"Emotion dysregulation in attention deficit hyperactivity disorder","volume":"171","author":"Shaw","year":"2014","journal-title":"Am J Psychiatry"},{"key":"bib3-20260219","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cpr.2016.04.011","article-title":"Attention-deficit hyperactivity disorder and children's emotion dysregulation: a meta-analysis","volume":"46","author":"Graziano","year":"2016","journal-title":"Clin Psychol Rev"},{"key":"bib4-20260219","doi-asserted-by":"crossref","first-page":"50","DOI":"10.3810\/pgm.2011.09.2459","article-title":"Toward defining deficient emotional self-regulation in children with attention-deficit\/hyperactivity disorder using the Child Behavior Checklist: a controlled study","volume":"123","author":"Spencer","year":"2011","journal-title":"Postgrad Med"},{"key":"bib6-20260219","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1111\/j.1469-7610.2010.02309.x","article-title":"The Child Behavior Checklist-Dysregulation Profile predicts substance use, suicidality, and functional impairment: a longitudinal analysis","volume":"52","author":"Holtmann","year":"2011","journal-title":"J Child Psychol Psychiatry"},{"key":"bib7-20260219","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1111\/j.1469-7610.2010.02217.x","article-title":"Emotional lability in children and adolescents with attention deficit\/hyperactivity disorder (ADHD): clinical correlates and familial prevalence","volume":"51","author":"Sobanski","year":"2010","journal-title":"J Child Psychol Psychiatry"},{"key":"bib8-20260219","first-page":"503","article-title":"The unique contribution of emotional impulsiveness to impairment in major life activities in hyperactive children as adults","volume":"49","author":"Barkley","year":"2010","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"bib10-20260219","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1007\/s10802-016-0227-8","article-title":"Are elevations in ADHD symptoms associated with physiological reactivity and emotion dysregulation in children?","volume":"45","author":"McQuade","year":"2017","journal-title":"J Abnorm Child Psychol"},{"key":"bib11-20260219","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1177\/1087054712452135","article-title":"Do ADHD children with and without child behavior checklist-dysregulation profile have different clinical characteristics, cognitive features, and treatment outcomes?","volume":"19","author":"Peyre","year":"2015","journal-title":"J Atten Disord"},{"key":"bib12-20260219","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jad.2015.05.069","article-title":"Child behavior checklist dysregulation profile in children with disruptive behavior disorders: a longitudinal study","volume":"186","author":"Masi","year":"2015","journal-title":"J Affect Disord"},{"key":"bib13-20260219","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.neubiorev.2017.08.010","article-title":"Pharmacotherapy of emotional dysregulation in adults with ADHD: a systematic review and meta-analysis","volume":"84","author":"Lenzi","year":"2018","journal-title":"Neurosci Biobehav Rev"},{"key":"bib14-20260219","doi-asserted-by":"crossref","first-page":"2922","DOI":"10.3390\/jcm11102922","article-title":"Methylphenidate use for emotional dysregulation in children and adolescents with ADHD and ADHD and ASD: a naturalistic study","volume":"11","author":"Ventura","year":"2022","journal-title":"J Clin Med"},{"key":"bib15-20260219","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1177\/070674371506000202","article-title":"The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine","volume":"60","author":"Pringsheim","year":"2015","journal-title":"Can J Psychiatry"},{"key":"bib16-20260219","doi-asserted-by":"crossref","first-page":"699687","DOI":"10.3389\/fpsyt.2021.699687","article-title":"The impact of persistent irritability on the medication treatment of paediatric attention deficit hyperactivity disorder","volume":"12","author":"Baweja","year":"2021","journal-title":"Front Psych"},{"key":"bib17-20260219","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.biopsych.2006.12.030","article-title":"The neuropsychological effects of chronic methylphenidate on drug-naive boys with attention-deficit\/hyperactivity disorder","volume":"62","author":"Coghill","year":"2007","journal-title":"Biol Psychiatry"},{"key":"bib18-20260219","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1089\/cap.2006.0018","article-title":"Emotional expression during attention-deficit\/hyperactivity disorders treatment: initial assessment of treatment effects","volume":"17","author":"Kratochvil","year":"2007","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"bib19-20260219","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1089\/cap.2015.0112","article-title":"Prevalence and treatment outcomes of persistent negative mood among children with attention-deficit\/hyperactivity disorder and aggressive behavior","volume":"26","author":"Blader","year":"2016","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"bib20-20260219","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1007\/s11920-013-0355-6","article-title":"Antipsychotic and psychostimulant drug combination therapy in attention deficit\/hyperactivity and disruptive behavior disorders: a systematic review of efficacy and tolerability","volume":"15","author":"Linton","year":"2013","journal-title":"Curr Psychiatry Rep"},{"issue":"Suppl 2","key":"bib21-20260219","doi-asserted-by":"crossref","first-page":"S124","DOI":"10.1542\/peds.2015-2851K","article-title":"Pharmacologic treatment of severe irritability and problem behaviors in autism: a systematic review and meta-analysis","volume":"137","author":"Fung","year":"2016","journal-title":"Pediatrics"},{"key":"bib22-20260219","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/cap.2018.0068","article-title":"Aripiprazole\/methylphenidate combination in children and adolescents with disruptive mood dysregulation disorder and attention-deficit\/hyperactivity disorder: an open-label study","volume":"28","author":"Pan","year":"2018","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"bib23-20260219","first-page":"1105","article-title":"Adult outcomes of childhood dysregulation: a 14-year follow-up study","volume":"49","author":"Althoff","year":"2010","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"bib24-20260219","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.jaac.2011.05.001","article-title":"Genome-wide association study of the child behavior checklist dysregulation profile","volume":"50","author":"Mick","year":"2011","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"bib25-20260219","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1089\/cap.2018.0070","article-title":"Irritability and maladaptation among children: the utility of Chinese versions of the Affective Reactivity Index and Aberrant Behavior Checklist-Irritability subscale","volume":"29","author":"Pan","year":"2019","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"bib26-20260219","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.neubiorev.2019.09.023","article-title":"Neurological and psychiatric adverse effects of long-term methylphenidate treatment in ADHD: a map of the current evidence","volume":"107","author":"Krinzinger","year":"2019","journal-title":"Neurosci Biobehav Rev"},{"key":"bib27-20260219","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1111\/jcpp.12823","article-title":"Practitioner review: definition, recognition, and treatment challenges of irritability in young people","volume":"59","author":"Stringaris","year":"2018","journal-title":"J Child Psychol Psychiatry"},{"key":"bib28-20260219","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1089\/cap.2023.0035","article-title":"Characteristic similarities of irritability between autism and disruptive mood dysregulation disorder","volume":"33","author":"Pan","year":"2023","journal-title":"J Child Adolesc Psychopharmacol"},{"key":"bib29-20260219","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/00004583-200102000-00011","article-title":"Clinical relevance of the primary findings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment","volume":"40","author":"Swanson","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"bib30-20260219","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/00004583-200111000-00015","article-title":"Psychometric properties of the strengths and difficulties questionnaire","volume":"40","author":"Goodman","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"bib31-20260219","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1097\/00004583-198726060-00015","article-title":"The Social Adjustment Inventory for Children and Adolescents (SAICA): testing of a new semistructured interview","volume":"26","author":"John","year":"1987","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"bib33-20260219","doi-asserted-by":"crossref","first-page":"6921","DOI":"10.1038\/s41598-023-33979-2","article-title":"Psychopharmacological treatment of disruptive behavior in youths: systematic review and network meta-analysis","volume":"13","author":"Seok","year":"2023","journal-title":"Sci Rep"},{"key":"bib34-20260219","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neubiorev.2018.02.001","article-title":"The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of attention-deficit\/hyperactivity disorder and other psychiatric comorbidities","volume":"87","author":"Faraone","year":"2018","journal-title":"Neurosci Biobehav Rev"},{"key":"bib35-20260219","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.tox.2010.01.009","article-title":"Identification of selected therapeutic agents as inhibitors of carboxylesterase 1: potential sources of metabolic drug interactions","volume":"270","author":"Zhu","year":"2010","journal-title":"Toxicology"},{"key":"bib36-20260219","first-page":"726","article-title":"Toward a revised nosology for attention-deficit\/hyperactivity disorder heterogeneity","volume":"5","author":"Nigg","year":"2020","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"}],"container-title":["Journal of Clinical Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0000000000002002","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T15:00:50Z","timestamp":1771513250000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/JCP.0000000000002002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,16]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/jcp.0000000000002002","relation":{},"ISSN":["1533-712X","0271-0749"],"issn-type":[{"value":"1533-712X","type":"electronic"},{"value":"0271-0749","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,16]]}}}